The DOI matches its Crossref record; 276 of the 278 references it cites were found in a registry or an index.
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Open accessPublished version of a preprint
Abstract
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised. This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process. The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text. The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites. “To maximise the benefit to society, you need to not just do research but do it well” Douglas G Altman
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Adapted from Steg et al. [182]](/paper-figures/7a5ba43922b94815b6414eed1fd37d47/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-1.jpg)
![Fig. 2 Redrawn from Gilson et al. [260] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made](/paper-figures/c4967b9adaa2452aa490488db9787f70/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-2.jpg)
![Fig. 3 Redrawn from Pallmann et al. [22] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made](/paper-figures/af5adb783a4949fe8b065e0c7ac619ff/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: Updated guideline for reporting randomised trials (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: updated guideline for reporting randomised trials (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Self-citationMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafé, A., Budzik, R. F., Bhuva, P., Yavagal, D. R., Ribó, M., Cognard, C., Hanel, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706442 · Cited by 5,667
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Self-citationConsort 2010 statement: extension to cluster randomised trials
Campbell, M. K., Piaggio, G., Elbourne, D. R., Altman, D. G., & for the CONSORT Group (2012) · BMJ · doi:10.1136/bmj.e5661 · Cited by 3,510
Self-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Self-citationAn improved Bonferroni procedure for multiple tests of significance
SIMES, R. J. (1986) · Biometrika · doi:10.1093/biomet/73.3.751 · Cited by 2,396
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 2,007
Self-citation
Research works printed but not linked: 4
- Detry MA, Lewis RJ, Broglio KR, et al. Standards for the design, conduct, and evaluation of adaptive randomized clinical trials. 2012. https://www.pcori.org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-Randomized-Clinical-Trials.pdf.
- Hack N, Brannath W. Estimation in adaptive group sequential trials; 2011.
- Vandemeulebroecke M. An investigation of two-stage tests. Stat Sin. 2006;16:933–51.
- Wagenmakers E-J, Gronau QF, Stefan A, et al. A Bayesian perspective on the proposed FDA guidelines for adaptive clinical trials. 2018. https://www.bayesianspectacles.org/a-bayesian-perspective-on-the-proposed-fda-guidelines-for-adaptive-clinical-trials/.
Cited by
Sorted by citations
CONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081123 · Cited by 1,195
Self-citationCONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00672-5 · Cited by 510
Self-citationHopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · JAMA · doi:10.1001/jama.2025.4347 · Cited by 444
Self-citationCONSORT 2025 statement: updated guideline for reporting randomized trials
Hopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03635-5 · Cited by 332
“Examples of extensions for trial designs include recommendations for adaptive designs 33 , cluster trials 34 , crossover trials 35 , early phase trials 36 , factorial trials 37 , non-inferiority and equivalence trials 38 , pragmatic trials 39 , multi-arm trials 40 , n-of-1 trials 41 , pilot and…”
Self-citationLuchini, C., Veronese, N., Nottegar, A., Shin, J. I., Gentile, G., Granziol, U., Soysal, P., Alexinschi, O., Smith, L., & Solmi, M. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2068 · Cited by 249
“transparency and improving the report of adaptive-design randomized trials, to increase both the interpretability of their results and reproducibility of their methods, results, and inference.(25)”
MethodReis, G., Silva, E. A. D. S. M., Silva, D. C. M., Thabane, L., Singh, G., Park, J., Forrest, J. I., Harari, O., dos Santos, C. V. Q., Almeida, A. P. F. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6468 · Cited by 135
“9) Age, y Median (IQR) 53 (18-81) 54 (18-94) 53 (18-80) 53 (18-94) >50 127 (59.”
BackgroundInfluentialCONSORT 2025 statement: Updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · PLOS Medicine · doi:10.1371/journal.pmed.1004587 · Cited by 139
“Examples of extensions for trial designs include recommendations for adaptive designs [33], cluster trials [34], crossover trials [35], early phase trials [36], factorial trials [37], non-inferiority and equivalence trials [38], pragmatic trials [39], multi-arm trials [40], n-of-1 trials [41],…”
Self-citationTarantini, G., Mojoli, M., Varbella, F., Caporale, R., Rigattieri, S., Andò, G., Cirillo, P. L., Pierini, S., Santarelli, A., Sganzerla, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.053 · Cited by 113
Burnett, T. D., Mozgunov, P., Pallmann, P., Villar, S. S., Wheeler, G., & Jaki, T. (2020) · BMC Medicine · doi:10.1186/s12916-020-01808-2 · Cited by 101
“Additionally, new reporting guidance for adaptive designs [200] has recently been published to facilitate uptake further.”
BackgroundSelf-citationHow to Use and Interpret the Results of a Platform Trial
Park, J., Detry, M. A., Murthy, S., Guyatt, G. H., & Mills, E. J. (2022) · JAMA · doi:10.1001/jama.2021.22507 · Cited by 86
Point estimation for adaptive trial designs I: A methodological review
Robertson, D. S., Choodari‐Oskooei, B., Dimairo, M., Flight, L., Pallmann, P., & Jaki, T. (2022) · Statistics in Medicine · doi:10.1002/sim.9605 · Cited by 56
Self-citationMiles, L. F., Burt, C. C., Arrowsmith, J. E., McKie, M. A., Villar, S. S., Govender, P., Shaylor, R., Tan, Z., Silva, R. D., & Falter, F. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003658 · Cited by 37
“(PDF) S1 Checklist.”
MethodInfluentialLee, K. M., Brown, L. C., Jaki, T., Stallard, N., & Wason, J. M. S. (2021) · Trials · doi:10.1186/s13063-021-05150-7 · Cited by 33
Self-citationPoint estimation for adaptive trial designs II : Practical considerations and guidance
Robertson, D. S., Choodari‐Oskooei, B., Dimairo, M., Flight, L., Pallmann, P., & Jaki, T. (2023) · Statistics in Medicine · doi:10.1002/sim.9734 · Cited by 28
“As highlighted by Dimairo et al.(2,3), the goal of clinical trials should be to provide reliable estimates of the treatment effect to inform accurate decision-making, but this can be compromised when an adaptive design is analysed with inappropriate statistical methods.”
BackgroundSelf-citationPerspectives on the application of CONSORT guidelines to randomised controlled trials in nutrition
Rigutto‐Farebrother, J., Ahles, S., Cade, J. E., Murphy, K. J., Plat, J., Schwingshackl, L., Roche, H. M., Shyam, S., Lachat, C. K., Minihane, A. M., et al. (2023) · European Journal of Nutrition · doi:10.1007/s00394-023-03137-5 · Cited by 28
Grayling, M. J., Bigirumurame, T., Cherlin, S., Ouma, L. O., Zheng, H., & Wason, J. M. S. (2021) · BMC Rheumatology · doi:10.1186/s41927-021-00192-5 · Cited by 25
“An adaptive design is one “that offers pre-planned opportunities to use accumulating trial data to modify aspects of an ongoing trial while preserving the validity and integrity of that trial” [17].”
Self-citationRandomised controlled trials in pre-hospital trauma: a systematic mapping review
Björklund, M. K., Cruickshank, M., Lendrum, R. A., & Gillies, K. (2021) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/s13049-021-00880-8 · Cited by 18
“As such, attention to the recent adaptive design CONSORT extension will be key for those designing adaptive trials in this context to ensure adequate reporting [52].”
BackgroundEarwaker, M., Villar, S. S., Fox-Rushby, J. A., Duckworth, M., Dawson, S. N., Steele, J., Chiu, Y., Litton, E., Kunst, G., Murphy, G. J., et al. (2022) · Trials · doi:10.1186/s13063-022-06180-5 · Cited by 13
Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Espinasse, A., Ursino, M., Patel, D., Kightley, A., Hughes, S., Jaki, T., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02937-0 · Cited by 16
Self-citationNine-month, all-oral regimens for rifampin-resistant tuberculosisPreprint
Guglielmetti, L., Khan, U. A., Velásquez, G. E., Gouillou, M., Abubakirov, A., Baudin, E., Berikova, E. A., Berry, C., Bonnet, M., Cellamare, M., et al. (2024) · medRxiv · doi:10.1101/2024.01.29.24301679 · Cited by 13
Xi, M., Dragsted, L. O., Tullin, M., Ernst, M., Zaharudin, N., & Barbera, G. L. (2020) · Metabolites · doi:10.3390/metabo11010011 · Cited by 10
“The contents reported throughout the paper were addressed according to each item demonstrated in both the CONSORT 2010 statement and Adaptive designs CONSORT Extension (ACE) statement [23,24].”
MethodGötte, H., Kirchner, M., Krisam, J., Allignol, A., Lamy, F.-X., Schüler, A., & Kieser, M. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2190 · Cited by 11
Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?
Branch‐Elliman, W., Lehmann, L. S., Boden, W. E., Ferguson, R. E., & Monach, P. A. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100614 · Cited by 10
Renz, B. W., Adrion, C., Klinger, C., Ilmer, M., D’Haese, J. G., Buhr, H.-J., Mansmann, U., Werner, J., & PyloResPres study group (2021) · BMJ Open · doi:10.1136/bmjopen-2021-056191 · Cited by 10
White, D. A., Pye, C., Ridsdale, K., Dimairo, M., Mooney, C., Wright, J. T., Young, T. A., Cheong, Y. C., Drakeley, A., Mathur, R., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-076434 · Cited by 8
“22 For progression of OHSS severity, a mixed effects logistic regression model adjusted for stratification factors (site as a random effect and OHSS severity as a fixed effect) will be used and an adjusted difference in hospital-isation rates will be obtained using the delta method via margins.”
MethodSelf-citationResponse adaptive randomisation in clinical trials: Current practice, gaps and future directions
Wilson, I., Julious, S. A., Yap, C., Todd, S., & Dimairo, M. (2025) · Statistical Methods in Medical Research · doi:10.1177/09622802251348183 · Cited by 8
“68 Adaptive trials, including those that use RAR, require additional safeguards to ensure both the confidentiality of interim data and that interim analyses to inform trial adaptations and related decision-making processes do not introduce operational biases that could harm the credibility of trial…”
Self-citationCONSORT 2025 statement: updated guideline for reporting randomized trials: a Korean translation
Hopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · Ewha Medical Journal · doi:10.12771/emj.2025.00409 · Cited by 8
“아울러 주요 CONSORT 확장(유해성[ 24 ], 결과[ 25 ], 비약물학적 치료[ 27 ]) 및 기타 관련 보고 가이드라인( TIDieR [ 28 ]) 설계[ 33 ], 군집 시 험[ 34 ], 교차 시험[ 35 ], 초기 단계 시험[ 36 ], 요인 시험[ 37 ], 비열 등성 및 동등성 시험[ 38 ], 실용적 시험[ 39 ], 다군 시험[ 40 ], n - of - 1 시험[ 41 ], 시범 및 타당성 시험[ 42 ], 사람 내 무작위 배정 시험 [ 43 ]에 대한 권장사항이 포함된다.”
Self-citationAdaptive design trials in eating disorder research: A scoping review
Edney, L. C., & Pellizzer, M. L. (2024) · International Journal of Eating Disorders · doi:10.1002/eat.24198 · Cited by 9
Granholm, A., Munch, M. W., Meier, N. F., Sjövall, F., Helleberg, M., Hertz, F. B., Kaas‐Hansen, B. S., Thorsen‐Meyer, H., Andersen, L. W., Rasmussen, B. S., et al. (2024) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.14441 · Cited by 6
Flight, L., Brennan, A., Chick, S. E., Förster, M., Julious, S. A., & Tharmanathan, P. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02566-6 · Cited by 4
Self-citationAdaptive clinical trials in surgery: A scoping review of methodological and reporting quality
Staibano, P., Oulousian, E., McKechnie, T., Thabane, A., Luo, S., Gupta, M. K., Zhang, H., Pasternak, J. D., Au, M., Parpia, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299494 · Cited by 4
Pyle, M., Loftus, L., Emsley, R., Freeman, D. H., Gillard, S., Gumley, A. I., Sierpatowska, J., Wood, L., O’Connor, R. C., Pfeiffer, P., et al. (2024) · Trials · doi:10.1186/s13063-024-08293-5 · Cited by 4
“In line with the Adaptive Designs CON-SORT Extension (ACE) statement [30], we report the unplanned changes in this protocol.”
ResultHosseini, R., Chen, Z., Goligher, E. C., Fan, E., Ferguson, N. D., Harhay, M. O., Sahetya, S. K., Urner, M., Yarnell, C. J., & Heath, A. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107560 · Cited by 6
Behal, M. L., Flannery, A. H., & Miano, T. A. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae134 · Cited by 4
Adaptive designs in dermatology clinical trials: Current status and future perspectives
Potvin, D., D’Angelo, P., Bennett, S., Jankićević, J., & Bissonnette, R. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20030 · Cited by 3
“32 The document provides insight on when it is particularly important to report any outcomes resulting from adaptive decisions.”
A landscape of methodology and implementation of adaptive designs in cancer clinical trials
Zhu, Y., Wang, W.-X., Cheuk, S.-K., Feng, G., Li, X.-G., Peng, J., Liu, Y., Yu, S.-R., Tang, J.-L., Chow, S.-C., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104402 · Cited by 3
Randomization in clinical trials with small sample sizes using group sequential designs
Bodden, D., Hilgers, R.-D., & König, F. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325333 · Cited by 3
“Adherence to the consolidated standards of reporting trials (CONSORT) guidelines, which call for transparent reporting of randomization and adaptive design features, is crucial to address these gaps [22,52].”
Confidence Intervals for Adaptive Trial Designs I: A Methodological Review
Robertson, D. S., Burnett, T. D., Choodari‐Oskooei, B., Dimairo, M., Grayling, M. J., Pallmann, P., & Jaki, T. (2025) · Statistics in Medicine · doi:10.1002/sim.70174 · Cited by 3
Self-citationConfidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
Robertson, D. S., Burnett, T. D., Choodari‐Oskooei, B., Dimairo, M., Grayling, M. J., Pallmann, P., & Jaki, T. (2025) · Statistics in Medicine · doi:10.1002/sim.70202 · Cited by 2
Self-citationPoonai, N., Arthur‐Hayward, V., Ali, S., Sabhaney, V. J., Doan, Q. H., Trottier, E. D., Gravel, J., Tran, N. A., Bhatt, M., Eltorki, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324515 · Cited by 2
“We will follow the CONSORT [35] (clinical trials) and ACE extension [36] (adaptive trials) guidelines for conduct and reporting.”
Cummings, J. L., Zhong, K., Ballard, C. G., Sano, M. C., & Mintzer, J. E. (2025) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100107 · Cited by 2
Therapeutics in hospitalised adult patients with COVID-19
Roche, N., & Chalmers, J. D. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020423 · Cited by 2
A maximum statistic for the one-sided location-scale alternative in the two-stage design
Murakami, H., & Neuhäuser, M. (2024) · Statistical Methods & Applications · doi:10.1007/s10260-024-00775-9 · Cited by 1
“Adaptive designs conduct a sequence of experiments and analyze the data from each stage separately, allowing for preplanned opportunities to modify the trial’s course based on accruing information, if necessary (Bauer and Köhne 1994; Pallmann et al. 2018; Dimairo et al. 2020).”
Thomas, M. J., Hughes, G., Cooke, K., Butler-Walley, S., Marshall, E., Bowyer, L., Wathall, S., Smith, J., Lawton, S., Brammar, J., et al. (2025) · NIHR Open Research · doi:10.3310/nihropenres.13930.1 · Cited by 1
Self-citationMahajan, M., Martín, L., Gaurav, K., & Suri, R. K. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127890 · Cited by 1
Adaptive designs were primarily used but inadequately reported in early phase drug trials
Wang, Y., Yao, M., Liu, J., Liu, Y., Ma, Y., Luo, X., Mei, F., Xiang, H., Zou, K., Li, L., et al. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02256-9 · Cited by 1
“…designs CONSORT Extension (ACE) statement, a reporting guidance for adaptive trials, was developed in 2020 to advise clinical researchers on how to report details of the adaptive design [18]; this statement is also considered a valid tool to evaluate the reporting quality of adaptive trials.”
Peng, Y., Lyu, P., & Peng, X. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.07.002 · Cited by 1
Smart, K. M., Abbott-Fleming, V., Birklein, F., Bruehl, S. P., Corcoran, E., Day, S. J., Ferraro, M. C., Grieve, S., Hilgers, R.-D., Ingram, C., et al. (2025) · PAIN Reports · doi:10.1097/pr9.0000000000001320 · Cited by 1
“22 We are not aware of any previous or ongoing CRPS trials using adaptive designs.”
Dawson, S. N., Chiu, Y., Earwaker, M., Klein, A. A., & Villar, S. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1814203/v1 · Cited by 1
Brinquedo terapêutico reduz a ansiedade em procedimentos odontológicos? Estudo clínico randomizado
Carvalho, M. T. F., Pinheiro, S. L., de Sant’Anna, G. R., & Duarte, D. A. (2021) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e6248.2021
Optimal unplanned design modification in adaptive two‐stage trials
Pilz, M., Herrmann, C., Rauch, G., & Kieser, M. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2228
Estimands in clinical drug development: from design to regulatory assessment
Mitroiu, M. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/723
Factors affecting mortality, morbidity and survival in pylorus-preserving pancreaticoduodenectomy
(2022) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.21238
Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Ursino, M., Espinasse, A., Patel, D., Kightley, A., Hughes, S., Jaki, T., et al. (2023) · doi:10.31222/osf.io/jtpz2
Self-citationRandomized Trial of Fetal Surgery for Severe Left Diaphragmatic Hernia
Deprest, J. A., Nicolaides, K. H., Benachi, A., & Gratacós, E. (2023) · CRC Press eBooks · doi:10.1201/b23252-6
Staibano, P., McKechnie, T., Thabane, A., Olteanu, D., Nanji, K., Zhang, H., Lunny, C., Au, M., Gupta, M. K., Pasternak, J. D., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303315
“In 2020, CONSORT published an extension for adaptive trials to guide ACT reporting [13].”
Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Espinasse, A., Ursino, M., Patel, D., Kightley, A., Hughes, S., Jaki, T., et al. (2023) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.76189
Self-citationLora, D., Blanco, A. L., de la Calle, G. M., Reyne, A. G., Ruiz‐Ruigómez, M., Sandubete, E. J. C., & Orenga, M. M. (2026) · Dialogues in Health · doi:10.1016/j.dialog.2026.100315
“Definitions of common ADCTs were derived from the literature [2,3,5,6,8,12] and are summarized in Table 1.”
Influential
Metadata
- Authors
- Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., Nicholl, J. P., Coates, E., Biggs, K., Hamasaki, T., Proschan, M. A., Scott, J. A., Ando, Y., Hind, D., Altman, D. G., on behalf of the ACE Consensus Group, Dimairo, M., Hamasaki, T., Todd, S., Weir, C. J., Mander, A. P., Wason, J., Koenig, F., Julious, S. A., Hind, D., Nicholl, J., Altman, D. G., Meurer, W. J., Cates, C., Sydes, M., Jemiai, Y., Ashby, D., Yap, C., Waldron-Lynch, F., Roger, J., Marsh, J., Collignon, O., Lawrence, D. J., Bunce, C., Parke, T., Gazzard, G., Coates, E., Walton, M. K., Hopewell, S., Pallmann, P., Jaki, T., Biggs, K., Proschan, M. A., Scott, J. A., & Ando, Y.
- Affiliations
- University of Sheffield (GB)
- University of Edinburgh (GB)
- Newcastle University (GB)
- Cardiff University (GB)
- ORCID
- Venue
- Trials
- Published
- 2020-06-17
- Volume
- 21
- Issue
- 1
- Pages
- 528-528
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC7298968
- OpenAlex
- W3000741148
- Cited by
- 58
- References
- 278
- Citations by year
- 2026: 1 · 2025: 17 · 2024: 14 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 5
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Trials (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Cancer Research UK (16895)
- National Institute for Health and Care Research (DRF-2012-05-182, SRF-2015-08-001)
- Department of Health and Social Care
- University of Sheffield
- Medical Research Council (NIHR-SRF-2015-08-001, MR/L004933/1, MR/L004933/2, MR/N028171/1, MC_UU_12023/24, MR/L004933/1-R/N/P/B1)
- NIHR Academy (SRF-2015-08-001)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Sociology and Political Science › Delphi Technique in Research
- Keywords
- adaptive design, CONSORT extension, reporting guidelines, randomised trials, research waste
- MeSH terms
- Delphi Technique, Humans, Periodicals as Topic, Publishing, Quality Control, Research Design, Reproducibility of Results, Randomized Controlled Trials as Topic, Guidelines as Topic, Consensus, Checklist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review